{
  "claims": [
    {
      "claim": "Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains.",
      "match_sources": [
        {
          "document_name": "FlublokPI",
          "matching_text": "Flublok is a vaccine indicated for active immunization for the prevention of disease",
          "score": 0.65
        },
        {
          "document_name": "FlublokPI",
          "matching_text": "antigenically resembling a strain represented in Flublok",
          "score": 0.65
        }
      ]
    },
    {
      "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
      "match_sources": [
        {
          "document_name": "Hsiao et al. (2023)",
          "matching_text": "vaccine (Flublok Quadrivalent) or one of two standard-dose influenza vaccines",
          "score": 0.76
        },
        {
          "document_name": "Hsiao et al. (2023)",
          "matching_text": "hemagglutinin influenza vaccine provides",
          "score": 0.75
        }
      ]
    },
    {
      "claim": "Cell- and egg-based flu vaccines have the potential to develop mutations during production, which may reduce their effectiveness.",
      "match_sources": [
        {
          "document_name": "Liu et al. (2024)",
          "matching_text": "vaccines have different egg-adapted mutation on the HA of the",
          "score": 0.78
        },
        {
          "document_name": "Liu et al. (2024)",
          "matching_text": "egg-based vaccines3. The potential of non-egg-based vaccines to miti-",
          "score": 0.73
        },
        {
          "document_name": "Liu et al. (2024)",
          "matching_text": "strating the potential of non-egg-based vaccines to reduce the neu-",
          "score": 0.73
        }
      ]
    },
    {
      "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
      "match_sources": [
        {
          "document_name": "Hsiao et al. (2023)",
          "matching_text": "that the recombinant vaccine may confer more",
          "score": 0.63
        },
        {
          "document_name": "Hsiao et al. (2023)",
          "matching_text": "unique characteristic of the recombinant vaccine is likely related",
          "score": 0.62
        }
      ]
    },
    {
      "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "match_sources": [
        {
          "document_name": "Liu et al. (2024)",
          "matching_text": "non-egg-based vaccines mounted higher post-vaccination HI antibody",
          "score": 0.8
        },
        {
          "document_name": "Hsiao et al. (2023)",
          "matching_text": "recombinant vaccine as compared with the standard-dose vaccines against each",
          "score": 0.78
        }
      ]
    },
    {
      "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "match_sources": [
        {
          "document_name": "FlublokPI",
          "matching_text": "The efficacy of Flublok Quadrivalent is relevant to Flublok because both vaccines are receive Flublok Quadrivalent or a Comparator inactivated influenza vaccine (Fluarix®)",
          "score": 0.81
        },
        {
          "document_name": "FlublokPI",
          "matching_text": "data for Flublok Quadrivalent are relevant to Flublok because both vaccines are ",
          "score": 0.79
        },
        {
          "document_name": "FlublokPI",
          "matching_text": "[14]). Data for Flublok Quadrivalent are relevant to Flublok because both vaccines are",
          "score": 0.78
        }
      ]
    },
    {
      "claim": "Flublok is produced using a novel production platform in which recombinant HA is expressed in insect cells using a baculovirus expression vector system (BEVS).",
      "match_sources": [
        {
          "document_name": "FlublokPI",
          "matching_text": "Flublok contains recombinant HA proteins of the three strains of inﬂuenza virus speciﬁed",
          "score": 0.67
        }
      ]
    },
    {
      "claim": "Recombinant HA antigens produced using BEVS have been shown to induce significantly higher levels of broadly cross-reactive antibodies against highly conserved regions of HA compared with egg-derived vaccines.",
      "match_sources": [
        {
          "document_name": "Arunachalam et al. (2021)",
          "matching_text": "IN RECOMBINANT HA VACCINE IS LIKELY TO FAVOUR ITS",
          "score": 0.71
        },
        {
          "document_name": "Arunachalam et al. (2021)",
          "matching_text": "the vaccine are inserted into the BEVS, from which high yields of ",
          "score": 0.69
        },
        {
          "document_name": "Arunachalam et al. (2021)",
          "matching_text": "recombinant HA vaccine thus provide a number of beneﬁts in vaccine performance which can be extended to other viral targets, ",
          "score": 0.69
        }
      ]
    },
    {
      "claim": "Flublok contains 45 micrograms (mcg) of HA per strain vs 15 mcg of HA per strain in a standard-dose influenza vaccine.",
      "match_sources": [
        {
          "document_name": "Grohskopf et al. (2023)",
          "matching_text": "60 µg of HA per vaccine virus (240 µg total) in a 0.7-mL dose",
          "score": 0.64
        }
      ]
    }
  ]
}